RMED - Ra Medical Systems, Inc. Stock Price, Fair Value and News

Market Closed

RMED Stock Price

View Fullscreen

RMED RSI Chart

RMED Valuation

Market Cap

4.8M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

10.61

EV/EBITDA

-0.05

Price/Free Cashflow

-0.45

RMED Price/Sales (Trailing)

RMED Profitability

Operating Margin

94.45%

EBT Margin

-15665.26%

Return on Equity

-36.96%

Return on Assets

-24.44%

Free Cashflow Yield

-221.09%

RMED Fundamentals

RMED Revenue

Revenue (TTM)

450.5K

Rev. Growth (Yr)

-3.53%

Rev. Growth (Qtr)

-29.61%

RMED Earnings

Earnings (TTM)

-6.8M

Earnings Growth (Yr)

95.97%

Earnings Growth (Qtr)

-299.85%

Breaking Down RMED Revenue

Last 7 days

0.5%

Last 30 days

-15.7%

Last 90 days

-49.5%

Trailing 12 Months

-93.3%

How does RMED drawdown profile look like?

RMED Financial Health

Current Ratio

0.83

RMED Investor Care

Shares Dilution (1Y)

43.79%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	450.5K	0	0	0
2023	90.0K	204.0K	337.0K	453.5K
2022	28.0K	24.0K	19.0K	14.0K
2021	1.8M	1.2M	602.0K	22.0K
2020	1.5M	1.8M	2.1M	2.3M
2019	7.0M	8.0M	7.8M	1.3M
2018	6.0M	6.1M	6.2M	6.3M
2017	0	0	0	5.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ra Medical Systems, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 23, 2023	meline susanne	acquired	-	-	2,575	-
Mar 23, 2023	caruso james joseph	acquired	-	-	1,779	-
Mar 23, 2023	jenkins david a	acquired	-	-	277,597	ex. chairman of the board
Mar 23, 2023	jenkins david a	acquired	-	-	711,967	ex. chairman of the board
Nov 20, 2022	mcguire jonathan will	sold (taxes)	-224	2.67	-84.00	ceo & secretary
May 20, 2022	mcguire jonathan will	sold (taxes)	-1,277	0.3013	-4,241	chief executive officer
May 20, 2022	jackson andrew c.	sold (taxes)	-410	0.3013	-1,361	cfo
Nov 22, 2021	mcguire jonathan will	sold	-21,350	2.62	-8,149	chief executive officer
Nov 22, 2021	jackson andrew c.	sold	-7,032	2.62	-2,684	cfo
Nov 20, 2021	jackson andrew c.	back to issuer	-	-	-11,759	cfo

Which funds bought or sold RMED recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	194	194	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	added	155	203,651	302,004	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	2.53	714	3,776	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	5,451	5,451	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	1.00	3.00	-%
May 14, 2024	Baird Financial Group, Inc.	unchanged	-	8,218	48,883	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	2,409	14,328	-%
May 13, 2024	Key Financial Inc	unchanged	-	-	1.00	-%
May 13, 2024	UBS Group AG	reduced	-2.95	724	5,044	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-10,000	-	-%

Are Funds Buying or Selling RMED?

Are funds buying RMED calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RMED

No. of Funds

Unveiling Ra Medical Systems, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	752,874	SC 13G
Mar 31, 2023	r. randall rollins voting trust u/a dated august 25, 1994	5.25%	261,553	SC 13G
Mar 29, 2023	jenkins david a	19.9%	991,828	SC 13D
Feb 15, 2022	lytton laurence w	0.8%	220,000	SC 13G/A
Jun 07, 2021	royce & associates lp	0.%	0	SC 13G/A
Mar 05, 2021	royce & associates lp	10.36%	302,583	SC 13G/A
Feb 16, 2021	lytton laurence w	7.7%	240,952	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	4.97%	152,610	SC 13G/A
Jan 27, 2021	royce & associates lp	6.96%	203,309	SC 13G
Aug 31, 2020	dean irwin & melissa burstein, as trustees u/t/a june 12, 2017	3.5%	2,559,201	SC 13G/A

Recent SEC filings of Ra Medical Systems, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	DEFA14A	DEFA14A
May 16, 2024	DEFA14A	DEFA14A
May 16, 2024	DEF 14A	DEF 14A
May 16, 2024	ARS	ARS
May 07, 2024	PRE 14A	PRE 14A
May 07, 2024	8-K	Current Report
May 06, 2024	10-Q	Quarterly Report
May 03, 2024	4	Insider Trading
May 03, 2024	3	Insider Trading
Apr 03, 2024	8-K	Current Report

Ra Medical Systems, Inc. News

Latest updates

Ra Medical Systems, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-29.6%	82,000	116,500	133,000	119,000	85,000	-	-	5,000	9,000	5,000	5,000	9,000	4,500	-	68,000	900,000	1,374,000	1,641,000	1,908,000	2,153,000	1,748,000
Cost Of Revenue	-28.6%	5,000	7,000	6,000	7,000	10,000	-	-	66,000	95,000	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-36.4%	77,000	121,000	127,000	89,000	75,000	-	-	-61,000	-86,000	-342,500	-241,000	-511,000	-443,000	-681,000	-500,000	-267,000	-210,000	-1,569,000	-517,000	-580,000	-194,000
Operating Expenses	-0.9%	2,693,000	2,718,000	2,857,000	6,397,000	66,559,000	8,215,000	4,783,000	8,399,000	5,417,000	7,921,500	7,153,000	6,227,000	6,427,000	9,426,000	7,007,000	9,849,000	7,580,000	3,148,000	17,071,000	14,768,000	14,760,000
S&GA Expenses	-2.7%	2,656,000	2,729,000	2,745,000	1,415,000	10,233,000	7,958,000	3,514,000	2,476,000	2,302,000	4,189,500	4,211,000	3,398,000	3,677,000	6,018,000	4,695,000	7,896,000	6,285,000	2,395,000	15,889,000	13,789,000	13,229,000
R&D Expenses	436.4%	37,000	-11,000	112,000	134,000	240,000	154,000	727,000	2,396,000	3,115,000	3,732,000	2,942,000	2,829,000	2,750,000	3,408,000	2,312,000	1,953,000	1,295,000	753,000	1,182,000	979,000	1,531,000
EBITDA Margin	-2.3%	-154	-150	-226	-390	-954	-1,888	-1,385	-1,193	-878	-1,165	-45.01	-22.93	-18.41	-14.16	-	-	-	-	-	-	-
Interest Expenses	-50.0%	3,000	6,000	-	17,000	181,000	-	-	-	-	-40,500	-	31,000	52,000	-6,000	5,000	15,000	25,000	-115,000	72,000	66,000	48,000
Income Taxes	-	-	-	-	-	-	3,000	-	-	-	2,000	-	-	-	-	-	-	-	7,000	3,000	5,000	-
Earnings Before Taxes	100.0%	-	-669,000	-1,927,000	-1,576,000	-66,400,000	-8,156,000	-4,763,000	-8,448,000	-5,495,000	-8,283,000	-7,378,000	-4,719,000	-6,877,000	-10,105,500	-7,515,000	-10,121,000	-7,701,000	-4,434,000	-17,415,000	-15,117,000	-14,674,000
EBT Margin	-0.7%	-156	-155	-231	-396	-975	-1,918	-1,420	-1,233	-924	-1,238	-48.30	-24.72	-19.65	-15.13	-	-	-	-	-	-	-
Net Income	-299.9%	-2,675,000	-669,000	-1,927,000	-1,576,000	-66,400,000	-8,159,000	-4,763,000	-8,448,000	-5,495,000	-8,287,000	-4,298,000	-5,249,000	-7,236,000	-10,444,000	-7,779,000	-10,121,000	-7,701,000	-9,743,000	-17,418,000	-15,122,000	-14,674,000
Net Income Margin	90.2%	-15.20	-155	-231	-396	-975	-1,918	-1,420	-1,105	-833	-1,139	-45.23	-25.98	-20.19	-15.39	-	-	-	-	-	-	-
Free Cashflow	-3.0%	-1,964,000	-1,907,000	-1,831,000	-4,867,000	-12,090,000	-3,042,000	-4,966,000	-6,008,000	-8,569,000	-5,752,000	-7,363,000	-6,677,000	-8,098,000	-9,409,000	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.8%	28,021	30,736	32,871	35,542	48,509	16,836	17,471	14,373	23,747	21,044	27,079	29,159	25,262	33,438	43,454	40,691	36,300	44,081	54,002	62,474	69,280
Current Assets	-53.0%	1,954	4,161	5,776	7,908	12,756	16,836	15,542	12,332	20,014	17,089	22,799	24,077	19,918	27,620	37,179	33,779	28,689	36,000	45,452	53,488	60,453
Cash Equivalents	-58.2%	1,491	3,565	5,579	7,410	12,218	15,859	13,657	11,128	17,652	15,045	20,616	20,220	15,954	23,906	33,646	29,380	18,437	14,584	14,512	11,787	55,129
Inventory	43.2%	63.00	44.00	64.00	59.00	70.00	-	-	43.00	1,059	986	997	2,323	2,249	877	2,592	2,704	2,773	1,292	2,572	2,344	2,217
Net PPE	15.7%	81.00	70.00	59.00	67.00	56.00	-	-	38.00	1,658	1,809	2,030	2,661	2,820	2,527	3,581	4,106	4,687	4,144	5,418	5,767	5,530
Liabilities	-0.5%	9,497	9,543	11,004	11,751	12,646	7,576	4,961	4,582	5,639	7,371	5,530	7,896	10,117	12,291	12,916	13,707	9,826	10,931	12,261	10,579	9,483
Current Liabilities	-4.9%	2,350	2,472	2,035	2,042	4,453	7,576	3,215	2,754	3,735	5,390	3,476	5,205	5,979	7,762	8,039	8,304	6,022	6,814	7,982	6,295	5,085
Shareholder's Equity	-12.6%	18,524	21,193	21,867	23,791	35,863	9,260	12,510	9,791	18,108	13,673	21,549	21,263	15,145	21,147	30,538	26,984	26,474	33,150	41,741	51,895	59,797
Retained Earnings	-1.0%	-278,384	-275,709	-275,040	-273,113	-271,537	-205,137	-196,978	-192,215	-183,767	-178,272	-169,985	-165,687	-160,438	-153,202	-142,758	-134,979	-124,858	-117,157	-107,414	-89,996	-74,874
Additional Paid-In Capital	0.0%	296,907	296,901	296,906	296,904	307,400	214,397	209,488	201,996	201,865	191,945	191,527	186,943	175,576	174,342	173,289	161,959	151,327	150,280	149,116	141,839	134,670
Shares Outstanding	7.8%	7,573	7,027	7,008	5,368	5,267	2,161	68,200	-	629	140	141	118	65.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,000	-	-	-	9,900	-	-	-	24,100	-	-	-	18,500	-	-	-	29,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-2.8%	-1,942	-1,889	-1,830	-4,847	-12,053	-3,025	-4,966	-6,008	-8,569	-5,711	-7,215	-6,621	-8,078	-9,414	-6,047	-5,800	-7,043	-9,572	-7,854	-6,803	-8,944
Share Based Compensation	220.0%	6.00	-5.00	2.00	-174	1,394	82.00	136	3.00	165	653	5.00	27.00	1,169	-22,013	48,000	100	1,047	8,144	400	500	7,745
Cashflow From Investing	-22.2%	-22.00	-18.00	-1.00	-20.00	-22.00	21.00	-	-	-	-1.00	3,345	169	289	5.00	-23.00	4,979	10,972	9,952	10,673	-36,492	-165
Cashflow From Financing	-2.8%	-110	-107	-	59.00	8,434	5,206	7,495	-516	11,176	141	4,266	10,718	-163	-331	10,336	11,764	-76.00	-308	-94.00	-47.00	-77.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RMED Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations (Unaudited)
Revenue	$ 82	$ 85
Cost of revenues	5	10
Gross profit	77	75
Operating expenses
Loss on impairment of goodwill	0	56,086
Selling, general and administrative	2,656	10,233
Research and development	37	240
Total operating expenses	2,693	66,559
Operating loss	(2,616)	(66,484)
Other income (expense), net
Interest income	30	69
Other income (expense), net	(3)	15
Change in fair value of royalties payable	(86)	0
Total other income (expense), net	(59)	84
Net loss	(2,675)	(66,400)
Deemed dividend - warrant inducement offer	0	(800)
Net loss attributable to common stockholders	$ (2,675)	$ (67,200)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.36)	$ (24.65)
Weighted average common shares used in computing net loss per share, basic and diluted	7,429,198	2,726,442

RMED Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 1,491,000	$ 3,565,000
Accounts receivable	73,000	137,000
Inventories	63,000	44,000
Prepaid expenses and other current assets	327,000	415,000
Total current assets	1,954,000	4,161,000
Property and equipment, net	81,000	70,000
Lease right-of-use assets	171,000	179,000
Intangible assets, net	25,807,000	26,318,000
Other non-current assets	8,000	8,000
TOTAL ASSETS	28,021,000	30,736,000
Current Liabilities
Accounts payable	543,000	464,000
Accrued expenses	1,640,000	1,733,000
Notes payable	74,000	184,000
Current portion of operating lease liabilities	93,000	91,000
Total current liabilities	2,350,000	2,472,000
Royalties payable	7,060,000	6,974,000
Operating lease liabilities	87,000	97,000
Total liabilities	9,497,000	9,543,000
Stockholders' Equity
Common stock, $0.0001 par value, 300,000,000 shares authorized; 7,573,403 and 7,026,627 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,000	1,000
Additional paid-in capital	296,907,000	296,901,000
Accumulated deficit	(278,384,000)	(275,709,000)
Total stockholders' equity	18,524,000	21,193,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	28,021,000	30,736,000
Series A convertible preferred stocks [Member]
Stockholders' Equity
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized Series A Convertible Preferred Stock, $0.0001 par value, 7,203 shares designated; 3,703 and 4,578 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Series x convertible preferred stocks [Member]
Stockholders' Equity
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized Series A Convertible Preferred Stock, $0.0001 par value, 7,203 shares designated; 3,703 and 4,578 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	$ 0	$ 0

About Ra Medical Systems, Inc.

Ra Medical Systems, Inc. Frequently Asked Questions

What is the ticker symbol for Ra Medical Systems, Inc.? What does RMED stand for in stocks?

RMED is the stock ticker symbol of Ra Medical Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ra Medical Systems, Inc. (RMED)?

As of Tue Apr 30 2024, market cap of Ra Medical Systems, Inc. is 4.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RMED stock?

You can check RMED's fair value in chart for subscribers.

What is the fair value of RMED stock?

You can check RMED's fair value in chart for subscribers. The fair value of Ra Medical Systems, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ra Medical Systems, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RMED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ra Medical Systems, Inc. a good stock to buy?

The fair value guage provides a quick view whether RMED is over valued or under valued. Whether Ra Medical Systems, Inc. is cheap or expensive depends on the assumptions which impact Ra Medical Systems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RMED.

What is Ra Medical Systems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, RMED's PE ratio (Price to Earnings) is -0.7 and Price to Sales (PS) ratio is 10.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RMED PE ratio will change depending on the future growth rate expectations of investors.